Drug Profile
Research programme: biodefence therapeutic - Navigen/University of Utah
Alternative Names: Slit2NLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator University of Utah
- Developer Navigen Pharmaceuticals
- Class Proteins
- Mechanism of Action Cadherin 5 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Systemic inflammatory response syndrome
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Systemic-inflammatory-response-syndrome in USA (Parenteral)
- 08 Dec 2010 Early research in Systemic inflammatory response syndrome in viral haemorrhagic fevers or anthrax infection in USA (Parenteral)